Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer

Background: As per facts sheet of WHO, cancer is a leading cause of mortality worldwide accounting nearly 10 million deaths in 2020. However, breast, lung, colon and rectum, prostate, skin and stomach cancers are the six most prevailing cancer across the globe. Out of the aforesaid cancers, breast c...

Full description

Bibliographic Details
Main Authors: Versha Tripathi, Pooja Jaiswal, Khageswar Sahu, Shovan Kumar Majumder, Dharmendra Kashyap, Hem Chandra Jha, Amit Kumar Dixit, Hamendra Singh Parmar
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Advances in Cancer Biology - Metastasis
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667394022000399
_version_ 1811188613026676736
author Versha Tripathi
Pooja Jaiswal
Khageswar Sahu
Shovan Kumar Majumder
Dharmendra Kashyap
Hem Chandra Jha
Amit Kumar Dixit
Hamendra Singh Parmar
author_facet Versha Tripathi
Pooja Jaiswal
Khageswar Sahu
Shovan Kumar Majumder
Dharmendra Kashyap
Hem Chandra Jha
Amit Kumar Dixit
Hamendra Singh Parmar
author_sort Versha Tripathi
collection DOAJ
description Background: As per facts sheet of WHO, cancer is a leading cause of mortality worldwide accounting nearly 10 million deaths in 2020. However, breast, lung, colon and rectum, prostate, skin and stomach cancers are the six most prevailing cancer across the globe. Out of the aforesaid cancers, breast cancer is the most commonly diagnosed cancer worldwide with 2.26 million cases in 2020. Summary: Metabolic alterations have been found to be associated with most of the cancers, suggesting that both loss of mitochondrial functioning (Warburg metabolism) as well as gain of mitochondrial functioning (OXPHOS) are contributing factor for cancer progression, invasion and metastasis. Here it is noteworthy that cancer is a heterogeneous mass of the cells and different cell types are having different tactics due to difference in tumor microenvironment, clonal selection, clonal evolution and cancer stem cell formation which resultantly affects the overall therapeutic response of the cancer therapies, chemo-resistance, radio-resistance, cancer stem cell formation, angiogenesis, migratory potential, invasion-metastasis cascade etc. Cancer cells are having a great metabolic plasticity which supports their survival, proliferation, invasion, metastasis and relapse. Variety of metabolic drugs are already in clinical practice for various metabolic disorders and are known for their proven safety and efficacy track record since decades and they have been reported for pleitropic influence on mitochondrial metabolism as well as biogenesis. Similarly, some other emerging pro- and anti-oxidative drugs for mitochondrial reactive oxygen species are also known to modulate mitochondrial functioning by various means. Therefore, present review sheds light on the potential of metabolic drugs and mitochondrial modulators on cancer pathologies and their underlying molecular mechanisms through which they may improve clinical outcomes and prognosis of cancer patients by many folds.
first_indexed 2024-04-11T14:22:52Z
format Article
id doaj.art-fcd5a0825b8f4a5f94c5d739fafea854
institution Directory Open Access Journal
issn 2667-3940
language English
last_indexed 2024-04-11T14:22:52Z
publishDate 2022-12-01
publisher Elsevier
record_format Article
series Advances in Cancer Biology - Metastasis
spelling doaj.art-fcd5a0825b8f4a5f94c5d739fafea8542022-12-22T04:19:01ZengElsevierAdvances in Cancer Biology - Metastasis2667-39402022-12-016100065Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancerVersha Tripathi0Pooja Jaiswal1Khageswar Sahu2Shovan Kumar Majumder3Dharmendra Kashyap4Hem Chandra Jha5Amit Kumar Dixit6Hamendra Singh Parmar7School of Biotechnology, Devi Ahilya University, Indore, 452001, M.P, IndiaSchool of Biotechnology, Devi Ahilya University, Indore, 452001, M.P, IndiaLaser Biomedical Applications Division, Raja Ramanna Centre for Advanced Technology, Indore, 452013, IndiaLaser Biomedical Applications Division, Raja Ramanna Centre for Advanced Technology, Indore, 452013, IndiaDepartment of Biosciences and Bioengineering, IIT, Simrol, Indore, IndiaDepartment of Biosciences and Bioengineering, IIT, Simrol, Indore, IndiaCentral Council for Research in Ayurvedic Sciences, Kolkata, West Bengal, IndiaSchool of Biotechnology, Devi Ahilya University, Indore, 452001, M.P, India; Corresponding author.Background: As per facts sheet of WHO, cancer is a leading cause of mortality worldwide accounting nearly 10 million deaths in 2020. However, breast, lung, colon and rectum, prostate, skin and stomach cancers are the six most prevailing cancer across the globe. Out of the aforesaid cancers, breast cancer is the most commonly diagnosed cancer worldwide with 2.26 million cases in 2020. Summary: Metabolic alterations have been found to be associated with most of the cancers, suggesting that both loss of mitochondrial functioning (Warburg metabolism) as well as gain of mitochondrial functioning (OXPHOS) are contributing factor for cancer progression, invasion and metastasis. Here it is noteworthy that cancer is a heterogeneous mass of the cells and different cell types are having different tactics due to difference in tumor microenvironment, clonal selection, clonal evolution and cancer stem cell formation which resultantly affects the overall therapeutic response of the cancer therapies, chemo-resistance, radio-resistance, cancer stem cell formation, angiogenesis, migratory potential, invasion-metastasis cascade etc. Cancer cells are having a great metabolic plasticity which supports their survival, proliferation, invasion, metastasis and relapse. Variety of metabolic drugs are already in clinical practice for various metabolic disorders and are known for their proven safety and efficacy track record since decades and they have been reported for pleitropic influence on mitochondrial metabolism as well as biogenesis. Similarly, some other emerging pro- and anti-oxidative drugs for mitochondrial reactive oxygen species are also known to modulate mitochondrial functioning by various means. Therefore, present review sheds light on the potential of metabolic drugs and mitochondrial modulators on cancer pathologies and their underlying molecular mechanisms through which they may improve clinical outcomes and prognosis of cancer patients by many folds.http://www.sciencedirect.com/science/article/pii/S2667394022000399AICARTigecyclineCordycepinMitochondrial redox modulatorsStatinsFibrates
spellingShingle Versha Tripathi
Pooja Jaiswal
Khageswar Sahu
Shovan Kumar Majumder
Dharmendra Kashyap
Hem Chandra Jha
Amit Kumar Dixit
Hamendra Singh Parmar
Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer
Advances in Cancer Biology - Metastasis
AICAR
Tigecycline
Cordycepin
Mitochondrial redox modulators
Statins
Fibrates
title Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer
title_full Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer
title_fullStr Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer
title_full_unstemmed Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer
title_short Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer
title_sort repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer
topic AICAR
Tigecycline
Cordycepin
Mitochondrial redox modulators
Statins
Fibrates
url http://www.sciencedirect.com/science/article/pii/S2667394022000399
work_keys_str_mv AT vershatripathi repurposingofmetabolicdrugsandmitochondrialmodulatorsasanemergingclassofcancertherapeuticswithaspecialfocusonbreastcancer
AT poojajaiswal repurposingofmetabolicdrugsandmitochondrialmodulatorsasanemergingclassofcancertherapeuticswithaspecialfocusonbreastcancer
AT khageswarsahu repurposingofmetabolicdrugsandmitochondrialmodulatorsasanemergingclassofcancertherapeuticswithaspecialfocusonbreastcancer
AT shovankumarmajumder repurposingofmetabolicdrugsandmitochondrialmodulatorsasanemergingclassofcancertherapeuticswithaspecialfocusonbreastcancer
AT dharmendrakashyap repurposingofmetabolicdrugsandmitochondrialmodulatorsasanemergingclassofcancertherapeuticswithaspecialfocusonbreastcancer
AT hemchandrajha repurposingofmetabolicdrugsandmitochondrialmodulatorsasanemergingclassofcancertherapeuticswithaspecialfocusonbreastcancer
AT amitkumardixit repurposingofmetabolicdrugsandmitochondrialmodulatorsasanemergingclassofcancertherapeuticswithaspecialfocusonbreastcancer
AT hamendrasinghparmar repurposingofmetabolicdrugsandmitochondrialmodulatorsasanemergingclassofcancertherapeuticswithaspecialfocusonbreastcancer